1. Home
  2. Directory
  3. New York
  4. Yonkers
  5. Physician Assistant
  6. NPI Profile
  7. Prescriptions 1164023172

BETINA CHARLOTTE APOSTOL NUGUID PA-C
Prescription History 1164023172
Physician Assistant in Yonkers, NY

NPI Status: Active since November 05, 2020

Contact Information

1730 CENTRAL PARK AVE STE 3P
YONKERS, NY
ZIP 10710
Phone: (914) 779-0141

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for BETINA CHARLOTTE APOSTOL NUGUID PA-C, an active Physician Assistant specialist practicing in Yonkers, NY. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 74 documented patient claims. Among these therapy options, the most frequently utilized medication is Prosol, which accounts for 38 claims alone.

Medication Index

C
L
P
S
No matching medications currently found on file.

Calcium Acetate

Generic Formulation: Calcium AcetateSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 12
30-Day Fills 19.4
Days Supply 582
NY State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills42.2
Peer Average Days Supply1,190
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.6% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,892.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$157.69

State Avg Cost Per Claim

$86.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Calcium acetate is used to prevent high blood phosphate levels in patients who are on dialysis due to severe kidney disease. Dialysis removes some phosphate from your blood, but it is difficult to remove enough to keep your phosphate levels balanced. Decreasing blood phosphate levels can help keep your bones strong, prevent unsafe buildup of minerals in your body, and possibly decrease the risk of heart disease and strokes that can result from high phosphate levels. Calcium acetate is a natural mineral that works by holding onto phosphate from the diet so that it can pass out of your body.

Lokelma

Generic Formulation: Sodium Zirconium CyclosilicateSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 12
30-Day Fills 13.3
Days Supply 396
NY State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills32.1
Peer Average Days Supply833
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.0% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,403.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$616.92

State Avg Cost Per Claim

$744.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat high levels of potassium in the blood. It works by binding to potassium in the gut. This medication does not work right away, and should not be used to treat life-threatening high levels of potassium. High potassium levels can cause symptoms such as nausea, muscle weakness/tiredness, irregular heartbeats, or paralysis.

Prosol

Generic Formulation: Parenteral Amino Acid 20% No.1Specialty: Physician Assistant
Provider Metrics Summary
Total Claims 38
30-Day Fills 38.0
Days Supply 266
NY State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills64.8
Peer Average Days Supply449
Conservative Utilization

This provider writes prescriptions for this formulation 40.6% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,159.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$162.09

State Avg Cost Per Claim

$160.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A ubiquitous phosphoprotein that serves as an intracellular substrate for a variety of SIGNAL TRANSDUCTION PATHWAYS. PHOSPHORYLATION of stathmin occurs during CELL CYCLE progression, and stathmin functions as a microtubule-destabilizing protein that promotes MICROTUBULE depolymerization during INTERPHASE and late MITOSIS. Stathmin is expressed at very high levels in a variety of human CANCERS.

Sevelamer Carbonate

Generic Formulation: Sevelamer CarbonateSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 12
30-Day Fills 17.5
Days Supply 525
NY State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills55.9
Peer Average Days Supply1,538
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.2% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,973.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$331.12

State Avg Cost Per Claim

$269.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A polymeric amine that binds phosphate and is used to treat HYPERPHOSPHATEMIA in patients with kidney disease.

Therapeutic Applications

Sevelamer is used to lower high blood phosphorus (phosphate) levels in patients who are on dialysis due to severe kidney disease. Dialysis removes some phosphate from your blood, but it is difficult to remove enough to keep your phosphate levels balanced. Decreasing blood phosphate levels can help keep your bones strong, prevent unsafe buildup of minerals in your body, and possibly decrease the risk of heart disease and strokes that can result from high phosphate levels. Sevelamer works by holding onto phosphate from the diet so that it can pass out of your body.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like BETINA CHARLOTTE APOSTOL NUGUID PA-C provides transparency into local medical care patterns within Yonkers, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Physician Assistant** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.